Teva Pharma (TEVA) Tops Q3 EPS by 11c; Raises Outlook

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.65, $0.11 better than the analyst estimate of $0.54. Revenue for the quarter came in at $4.5 billion versus the consensus estimate of $4.53 billion.

GUIDANCE:

Teva Pharma sees FY2018 EPS of $2.80-$2.95, versus prior of $2.55-$2.80 and the consensus of $2.78.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
• Wall Street scrambles to lift Micron price targets ahead of earnings
• JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral